Overview of RCC: Clear-Cell and Non–clear Cell
Medical experts give an overview of renal cell carcinoma (RCC), detailing the differences between clear cell and non–clear cell subtypes, the various forms of non–clear cell RCC, and the demographic and risk factor profiles associated with each subtype, while also discussing how histological differences influence prognosis.
EP: 1.Overview of RCC: Clear-Cell and Non–clear Cell
EP: 2.Challenges in Treating RCC From Community and Academic Settings
EP: 3.Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
EP: 4.KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice
EP: 5.nccRCC: Alternative Therapies
EP: 6.Role of Histology and Data in Selecting Optimal Therapy in nccRCC
EP: 7.AE Management of IO/TKI and Future of nccRCC
EP: 8.KEYNOTE-564: Pembrolizumab as Adjuvant Therapy
EP: 9.NCCN Guideline Updates in Clear-Cell RCC
EP: 10.Best Treatment Selection in Clear-Cell RCC
Video content above is prompted by the following:
- Provide an overview of renal cell carcinoma (RCC), including differentiation between clear cell and non-con–clear cell types.
- Describe the subtypes of nccRCC.
- Who is typically affected by nccRCC versus vs ccRCC? What are the specific risk factors or demographic patterns?
How does histology impact prognosis?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
